South Korea obesity drug prescriptions have exceeded 1.1 million, sparking concerns about misuse for cosmetic purposes rather than medical needs. The figures highlight a growing debate about the balance between health benefits and risks.
Data shows Saxenda accounted for more than 720,000 prescriptions, while Wegovy recorded nearly 400,000. Together, these numbers reveal how quickly demand has grown. Women represented over 70 percent of patients, and people in their 30s and 40s made up about 60 percent.
South Korea obesity drug prescriptions also reflect geographic concentration. Seoul accounted for over 40 percent of the total, while Gyeonggi Province represented nearly a quarter. This regional pattern suggests urban demand drives much of the market.
Doctors prescribe these drugs for patients with a body mass index above 30 or above 27 with related conditions. However, health officials warn that many individuals without medical need may seek the drugs for appearance-based reasons. This raises questions about oversight and regulation.
Adverse reactions further complicate the issue. Authorities logged more than 1,700 cases of side effects, including nausea, vomiting, headaches, itching, and rashes. While many reactions appear mild, they underscore potential risks when drugs are used without medical necessity.
Lawmakers have voiced strong concerns. Representative Seo Mi-hwa emphasized the importance of strict BMI checks before approving prescriptions. She stressed that stronger oversight must prevent misuse and protect public health.
South Korea obesity drug prescriptions highlight both rising awareness of weight control and the dangers of overuse. Demand reflects social pressure, particularly among younger and middle-aged women in metropolitan areas. Critics argue that cosmetic motivations overshadow genuine medical need, increasing risks.
Meanwhile, the rapid increase in prescriptions suggests cultural and social factors play as much of a role as health concerns. South Korea’s focus on appearance and fitness likely fuels this surge, raising broader societal questions.
Officials now face a challenge. They must balance accessibility for patients who need the treatment with safeguards to prevent misuse. This requires tighter monitoring, stricter rules, and stronger awareness campaigns to guide safe use.
